Encouraging preliminary data for Epidiolex
08:15 AM ET • GWPH
GW Pharmaceuticals (GWPH) reports preliminary data on 27 children and young adults with treatment-resistant epilepsy who have been treated with its investigational cannabidiol product candidate Epidiolex for a period of 12 weeks. Of the 27 patients, nine have Dravet syndrome and the remaining 18 have treatment-resistant epilepsies with convulsive and/or non-convulsive siezures.
The mean overall reduction in seizure frequency compared to baseline was 44%. The median overall reduction was 42%.
At the end of 12 weeks, 48% of the patients achieved at least a 50% reduction in seizure frequency compared to baseline. 41% of the patients achieved at least a 70% reduction. 22% of the patients achieved at least a 90% reduction and 15% of the patients were seizure-free.
For the nine Dravet syndrome patients, 56% achieved at least a 50% reduction in seizure frequency, 44% achieved at least a 70% reduction and 33% achieved at least a 90% reduction (all were seizure-free).
Shares of GWPH are up 6% premarket on